A paper by Ruiheng Tang "Antibody therapeutics with high affinity for FcγRs exacerbate anaphylaxis via FcγR-mediated capture by tumor-associated myeloid cells" has been accepted in J ImmunoTher Cancer (IF=10.6). Previously, we found that antibodies with high affinity for Fcγ receptors induce anaphylaxis in tumor-bearing mice (Arai T, et al. J ImmunoTher Cancer, 2022). This study investigated why differences in Fcγ receptor affinity affect the risk of anaphylaxis. We revealed that cancer-associated myeloid cells recognize antibody drugs via Fcγ receptors and present them as antigens, leading to increased production of anti-drug antibodies (ADA) and subsequent anaphylaxis.

This study is a collaborative work with Dr. Akiko Ishii at National Institute of Health Sciences, Dr. Kyohei Higashi at Faculty of Pharmaceutical Sciences, Tokyo University of Science, and Dr. Hiroto Kawashima at the Graduate School of Pharmaceutical Sciences, Chiba university.